Wordt geladen...
PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
BACKGROUND: PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson’s disease. METHODS: A 15-week, phase II, double-blind, placebo-controlled clinical trial was conducted to assess the...
Bewaard in:
| Gepubliceerd in: | Ther Adv Neurol Disord |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7066585/ https://ncbi.nlm.nih.gov/pubmed/32201505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420911296 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|